A Phase 3 interventional study of liraglutide and placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 13th largest by enrollment, is one of 12 that started in 2017, is one of 17 in phase 3, and was the 34th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 12 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 61st largest by enrollment of the 166 interventional ones that give a count, is one of 7 that started in 2017, is one of 62 in phase 3, and was the 26th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obesity in a primary care setting according to Centers for Medicare \& Medicaid Services (CMS) visit schedule).
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 282 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide · Behavioral: CMS Intensive Behavior Therapy
Drug: placebo · Behavioral: CMS Intensive Behavior Therapy
Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
Intensive Behaviour Therapy for obesity
Change in Body Weight (%)
Observed mean change in body weight from baseline (week 0) to week 56 was evaluated for two different observation periods. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which subjects are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs). The test of superiority of liraglutide to placebo for the treatment policy estimand was tested in a hierarchical manner for the two primary and the consequent 7 confirmatory secondary endpoints presented.
Time frame: Week 0, week 56
Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56
The estimated mean percentage of subjects losing at least 5% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 56
Proportion of Subjects Losing More Than 10% of Baseline Body Weight at Week 56
The estimated mean percentage of subjects losing more than 10% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 56
Proportion of Subjects Losing More Than 15% of Baseline Body Weight at Week 56
The estimated mean percentage of subjects losing more than 15% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 56
Proportion of Subjects Losing 4% or More of Baseline Body Weight
The estimated mean percentage of subjects losing 4% or more of baseline body weight at week 16 is presented. The endpoint was evaluated for treatment policy estimand (in-trial data).
Time frame: Week 16
Change in Waist Circumference (cm)
Observed mean change from baseline in waist circumference. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 0, week 56
Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score
SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical functioning score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 0, week 56
Change in IWQoL-Lite for CT, Physical Function Domain (5-items) Score
Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trials Version (IWQoL-Lite for CT ) score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 0, week 56
Change in Six Minutes Walking Distance Test (6MWT)
Observed mean change from baseline in 6 minutes walking distance test. The 6MWT is a common test of functional exercise capacity that assesses the distance a subject can walk in 6 minutes. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 0, week 56
Change From Baseline in HbA1c (%)
Observed mean change from baseline to week 56 in glycosylated haemoglobin (HbA1c). Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline in FPG (mg/dL)
Observed mean change from baseline (week 0) in fasting plasma glucose (FPG). Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline sBP (mmHg)
Observed mean change in systolic blood pressure from baseline to week 56.
Time frame: Week 0, week 56
Change From Baseline dBP (mmHg)
Observed mean change from baseline (week 0) to week 56 in diastolic blood pressure (dBP). Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline in Lipids -Total Cholesterol
Observed mean change from baseline (week 0) to week 56 in total cholesterol (TC). Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline in Lipids - LDL Cholesterol
Observed mean change from baseline in low density cholesterol (LDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline in Lipids - HDL Cholesterol
Observed mean change from baseline in high density (HDL) cholesterol from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline in Lipids - VLDL Cholesterol
Observed mean change from baseline in very low density cholesterol (VLDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline in Lipids - TG
Observed mean change from baseline in triglyceride (TG) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change From Baseline in Lipids - FFA
Observed mean change from baseline in free fatty acids (FFA) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change in Short Form-36 v2.0 Acute (SF-36) (Subdomains)
SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in in the sub-domain scores is presented. A positive change score indicates an improvement since baseline. Results are evaluated based on in-trial data.
Time frame: Week 0, week 56
Change in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS))
Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain physical component summary (PCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical component summary (PCS) score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 0, week 56
Change in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS)
Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain mental component summary (MCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 mental component summary is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.
Time frame: Week 0, week 56
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score
Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) domain pain and discomfort. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score
Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) psychosocial domain. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score
Observed mean change from baseline (week 0) to week 56 in IWQoL-Lite for CT total score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.
Time frame: Week 0, week 56
Change in Weight Related Sign and Symptom (WRSS) Measure, Total Score
Observed mean change from baseline (week 0) to week 56 in WRSS measure, total score. The WRSS measures the presence and bothersome associated with weight-related symptoms. The WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint "Weight related sign and symptom (WRSS) measure, total score" couldn't be analysed.
Time frame: Week 0, week 56
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score
Percentage of subjects who achieved ≥ 4.3 T-score points increase from baseline in SF-36 physical functioning score at week 56 is presented. Results based on FAS in-trial data is presented.
Time frame: Week 56
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score
Percentage of subjects who achieved ≥ 3.8 T-score points increase from baseline in SF-36 physical component score at week 56 is presented. Results based on FAS in-trial data is presented.
Time frame: Week 56
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score
Percentage of subjects who achieved ≥ 4.6 T-score points increase from baseline in SF-36 mental component score at week 56 is presented. Results based on FAS in-trial data is presented.
Time frame: Week 56
Responder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score
Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score' was defined as '≥ 20 responder definition value for IWQoL-Lite for CT physical function domain (5-items) score. Percentage of subjects considered IWQoL-Lite for CT physical function domain score responders (increase of ≥20 points) at week 56 is presented. Results based on FAS in-trial data is presented.
Time frame: Week 56
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product
Adherence to trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to trial product is presented.
Time frame: Week 0, week 56
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet
Adherence to caloric diet is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet is presented.
Time frame: Week 0, week 56
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity
Adherence to physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to physical activity is presented.
Time frame: Week 0, week 56
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity
Adherence to caloric diet and physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet and physical activity is presented.
Time frame: Week 0, week 56
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product
Adherence to caloric diet, physical activity and trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet, physical activity and trial product is presented.
Time frame: Week 0, week 56
AEs From Randomisation Until and Including the Follow-up Period
Number of adverse events from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on SAS on-drug data is presented.
Time frame: Week 0 to week 56+30 days
Change in Physical Examination
Observed change from baseline to week 56 in physical examination are categorised under parameters namely abdomen, gastrointestinal system, cardiovascular system, central and peripheral nervous system, general appearence, head, ears, eyes, nose, throat and neck, lymph node palpation, musculoskeletal system, respiratory system, skin and thyroid gland. The percentage of subjects assessed as normal, abnormal not clinically significant and abnormal clinically significant at baseline and week 56 is presented.
Time frame: Week 1, week 56
Change in Resting Pulse
Observed mean change in pulse rate measured at resting position is presented.
Time frame: Week 0, week 56
Change in ECG
The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of subjects in each ECG category at baseline and week 56 are presented.
Time frame: Week -1, week 56
Change in Laboratory Measurements: Haematology (Haemoglobin Blood)
Observed mean change from baseline in haematological parameter blood haemoglobin.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Haematology (Haematocrit Blood)
Observed mean change from baseline in haematological parameter blood haematocrit. Haematocrit is presented as the percentage of red blood cells in total blood. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Haematology (Erythrocytes)
Observed mean change from baseline in haematological parameter - erythrocytes.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Haematology (Thrombocytes and Leukocytes)
Observed mean change from baseline in haematological parameters - thrombocytss and leukocytes.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (Albumin)
Observed mean change from baseline in biochemical parameter - albumin. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase)
Observed mean change from baseline in biochemical parameters - alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (Bilirubin and Creatinine)
Observed mean change from baseline in biochemical parameters - bilirubin and creatinine. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (Total Calcium, Pottassium, Sodium and Urea)
Observed mean change from baseline in biochemical parameters - total calcium, pottassium, sodium and urea. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (C-reactive Protein and Uric Acid)
Observed mean change from baseline in biochemical parameters - high sensitive c-reactive protein and uric acid. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum)
Observed mean change from baseline in biochemical parameters - estimated glomerular filtration rate. Serum GFR is estimated using MDRD formula . Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (Calcitonin)
Observed mean change from baseline in biochemical parameter - calcitonin. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
Change in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone)
Observed mean change from baseline in biochemical parameters - thyroid stimulating hormone. Results based on SAS on-drug data is presented.
Time frame: Week 0, week 56
The trial was conducted at 17 sites in the United States.
| Milestone | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Started | 142 | 140 |
| Completed | 114 | 103 |
| Not completed | 28 | 37 |
| Withdrew: Adverse event | 12 | 6 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 6 |
| Withdrew: Unclassified | 13 | 22 |
Observed mean change in body weight from baseline (week 0) to week 56 was evaluated for two different observation periods. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which subjects are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs). The test of superiority of liraglutide to placebo for the treatment policy estimand was tested in a hierarchical manner for the two primary and the consequent 7 confirmatory secondary endpoints presented.
| percent change | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | -7.4 ± 7.9 | -4.0 ± 7.4 |
| On-drug observation period | -9.1 ± 7.4 | -4.8 ± 7.6 |
The estimated mean percentage of subjects losing at least 5% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.
| percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 61.47 | 38.82 |
| On-drug observation period | 64.08 | 38.57 |
The estimated mean percentage of subjects losing more than 10% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.
| percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 30.45 | 19.75 |
| On-drug observation period | 33.80 | 19.29 |
The estimated mean percentage of subjects losing more than 15% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.
| percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 18.11 | 8.92 |
| On-drug observation period | 20.42 | 8.57 |
The estimated mean percentage of subjects losing 4% or more of baseline body weight at week 16 is presented. The endpoint was evaluated for treatment policy estimand (in-trial data).
| percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Proportion of Subjects Losing 4% or More of Baseline Body Weight | 78.73 | 52.70 |
Observed mean change from baseline in waist circumference. The endpoint was evaluated based on in-trial data and on-drug data.
| cm | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | -9.27 ± 9.22 | -6.91 ± 8.22 |
| On-drug observation period | -10.46 ± 9.22 | -7.24 ± 8.67 |
SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical functioning score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.
| Scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 3.55 ± 6.98 | 4.21 ± 6.85 |
| On-drug observation period | 4.03 ± 6.49 | 4.77 ± 6.03 |
Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trials Version (IWQoL-Lite for CT ) score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. The endpoint was evaluated based on in-trial data and on-drug data.
| Scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 13.5 ± 21.4 | 15.5 ± 23.0 |
| On-drug observation period | 15.2 ± 21.4 | 17.5 ± 21.4 |
Observed mean change from baseline in 6 minutes walking distance test. The 6MWT is a common test of functional exercise capacity that assesses the distance a subject can walk in 6 minutes. The endpoint was evaluated based on in-trial data and on-drug data.
| meter | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 47 ± 59 | 49 ± 69 |
| On-drug observation period | 53 ± 61 | 51 ± 69 |
Observed mean change from baseline to week 56 in glycosylated haemoglobin (HbA1c). Results based on FAS in-trial data is presented.
| percentage | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in HbA1c (%) | -0.2 ± 0.3 | -0.1 ± 0.2 |
Observed mean change from baseline (week 0) in fasting plasma glucose (FPG). Results based on FAS in-trial data is presented.
| mg/dL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in FPG (mg/dL) | -4.04 ± 9.59 | -0.28 ± 11.46 |
Observed mean change in systolic blood pressure from baseline to week 56.
| mmHg | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline sBP (mmHg) | -2 ± 14 | -1 ± 13 |
Observed mean change from baseline (week 0) to week 56 in diastolic blood pressure (dBP). Results based on FAS in-trial data is presented.
| mmHg | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline dBP (mmHg) | -1 ± 11 | -1 ± 10 |
Observed mean change from baseline (week 0) to week 56 in total cholesterol (TC). Results based on FAS in-trial data is presented.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Lipids -Total Cholesterol | -0.01 ± 0.59 | 0.00 ± 0.77 |
Observed mean change from baseline in low density cholesterol (LDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Lipids - LDL Cholesterol | -0.01 ± 0.52 | -0.01 ± 0.64 |
Observed mean change from baseline in high density (HDL) cholesterol from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Lipids - HDL Cholesterol | 0.06 ± 0.19 | 0.02 ± 0.22 |
Observed mean change from baseline in very low density cholesterol (VLDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Lipids - VLDL Cholesterol | -0.06 ± 0.31 | -0.01 ± 0.26 |
Observed mean change from baseline in triglyceride (TG) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Lipids - TG | -0.19 ± 1.04 | -0.01 ± 0.58 |
Observed mean change from baseline in free fatty acids (FFA) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change From Baseline in Lipids - FFA | -0.07 ± 0.28 | -0.06 ± 0.31 |
SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in in the sub-domain scores is presented. A positive change score indicates an improvement since baseline. Results are evaluated based on in-trial data.
| scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Bodily Pain | 0.67 ± 7.61 | 1.21 ± 8.88 |
| General Health Perception | 1.89 ± 6.31 | 1.08 ± 6.62 |
| Mental Health | -0.93 ± 7.80 | -0.68 ± 6.89 |
| Role Lim Emotion Prob | -1.27 ± 7.72 | -2.21 ± 8.59 |
| Role Lim. Phy Health | 2.01 ± 6.55 | 2.11 ± 7.68 |
| Social Functioning | 1.22 ± 8.69 | -0.45 ± 9.61 |
| Vitality | 2.64 ± 8.99 | 2.43 ± 7.78 |
Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain physical component summary (PCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical component summary (PCS) score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.
| scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS)) | 3.41 ± 6.65 | 3.83 ± 7.22 |
Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain mental component summary (MCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 mental component summary is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.
| scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS) | -1.22 ± 8.74 | -2.20 ± 8.11 |
Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) domain pain and discomfort. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.
| scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score | 10.1 ± 21.2 | 8.6 ± 23.1 |
Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) psychosocial domain. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.
| score | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score | 13.5 ± 20.3 | 12.4 ± 21.8 |
Observed mean change from baseline (week 0) to week 56 in IWQoL-Lite for CT total score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.
| scores on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score | 13.2 ± 18.5 | 12.8 ± 20.7 |
Observed mean change from baseline (week 0) to week 56 in WRSS measure, total score. The WRSS measures the presence and bothersome associated with weight-related symptoms. The WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint "Weight related sign and symptom (WRSS) measure, total score" couldn't be analysed.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Weight Related Sign and Symptom (WRSS) Measure, Total Score | NA ± NA | NA ± NA |
Percentage of subjects who achieved ≥ 4.3 T-score points increase from baseline in SF-36 physical functioning score at week 56 is presented. Results based on FAS in-trial data is presented.
| percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score | 38.7 | 37.9 |
Percentage of subjects who achieved ≥ 3.8 T-score points increase from baseline in SF-36 physical component score at week 56 is presented. Results based on FAS in-trial data is presented.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score | 43.7 | 41.4 |
Percentage of subjects who achieved ≥ 4.6 T-score points increase from baseline in SF-36 mental component score at week 56 is presented. Results based on FAS in-trial data is presented.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score | 20.4 | 9.3 |
Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score' was defined as '≥ 20 responder definition value for IWQoL-Lite for CT physical function domain (5-items) score. Percentage of subjects considered IWQoL-Lite for CT physical function domain score responders (increase of ≥20 points) at week 56 is presented. Results based on FAS in-trial data is presented.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Responder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score | 37.3 | 34.3 |
Adherence to trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to trial product is presented.
| weeks | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product | 49.5 ± 14.0 | 46.8 ± 16.1 |
Adherence to caloric diet is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet is presented.
| weeks | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet | 38.4 ± 16.0 | 36.1 ± 17.3 |
Adherence to physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to physical activity is presented.
| weeks | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity | 29.0 ± 17.1 | 30.0 ± 17.2 |
Adherence to caloric diet and physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet and physical activity is presented.
| weeks | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity | 24.0 ± 16.0 | 24.5 ± 15.7 |
Adherence to caloric diet, physical activity and trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet, physical activity and trial product is presented.
| weeks | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product | 22.9 ± 16.1 | 24.0 ± 15.9 |
Number of adverse events from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on SAS on-drug data is presented.
| events | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| AEs From Randomisation Until and Including the Follow-up Period | 867 | 601 |
Observed change from baseline to week 56 in physical examination are categorised under parameters namely abdomen, gastrointestinal system, cardiovascular system, central and peripheral nervous system, general appearence, head, ears, eyes, nose, throat and neck, lymph node palpation, musculoskeletal system, respiratory system, skin and thyroid gland. The percentage of subjects assessed as normal, abnormal not clinically significant and abnormal clinically significant at baseline and week 56 is presented.
| participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Abdomen (week -1) Normal | 108 | 121 |
| Abdomen (week -1) Abnormal, NCS | 34 | 19 |
| Abdomen (week -1) Abnormal CS | 0 | 0 |
| Abdomen (week 56) Normal | 114 | 108 |
| Abdomen (week 56) Abnormal, NCS | 25 | 12 |
| Abdomen (week 56) Abnormal, CS | 0 | 2 |
| Gastrointestinal System (week -1) Normal | 130 | 129 |
| Gastrointestinal System (week -1) Abnormal NCS | 12 | 11 |
| Gastrointestinal System (week -1) Abnormal CS | 0 | 0 |
| Gastrointestinal System (week 56) Normal | 132 | 116 |
| Gastrointestinal System (week 56) Abnormal NCS | 7 | 6 |
| Gastrointestinal System (week 56) Abnormal CS | 0 | 0 |
| Cardiovascular System (week-1) Normal | 136 | 127 |
| Cardiovascular System (week-1) Abnormal NCS | 6 | 13 |
| Cardiovascular System (week-1) Abnormal CS | 0 | 0 |
| Cardiovascular System (week 56) Normal | 138 | 116 |
| Cardiovascular System (week 56) Abnormal NCS | 1 | 5 |
| Cardiovascular System (week 56) Abnormal CS | 0 | 1 |
| Nervous System (week -1) Normal | 135 | 127 |
| Nervous System (week -1) Abnormal NCS | 5 | 6 |
| Nervous System (week -1) Abnormal CS | 2 | 7 |
| Nervous System (week 56) Normal | 132 | 112 |
| Nervous System (week 56) Abnormal NCS | 6 | 9 |
| Nervous System (week 56) Abnormal CS | 1 | 1 |
| General Appearance (week -1) Normal | 118 | 123 |
| General Appearance (week -1) Abnormal NCS | 24 | 17 |
| General Appearance (week -1) Abnormal CS | 0 | 0 |
| General Appearance (week 56) Normal | 122 | 112 |
| General Appearance (week 56) Abnormal NCS | 17 | 10 |
| General Appearance (week 56) Abnormal CS | 0 | 0 |
| Head, ENTand Neck (week -1) Normal | 129 | 128 |
| Head, ENTand Neck (week -1) Abnormal NCS | 13 | 12 |
| Head, ENTand Neck (week -1) Abnormal CS | 0 | 0 |
| Head, ENTand Neck (week 56) Normal | 126 | 115 |
| Head, ENTand Neck (week 56) Abnormal NCS | 13 | 7 |
| Head, ENTand Neck (week 56) Abnormal CS | 0 | 0 |
| Lymph Node Palpation (week -1) Normal | 142 | 140 |
| Lymph Node Palpation (week -1) Abnormal NCS | 0 | 0 |
| Lymph Node Palpation (week -1) Abnormal CS | 0 | 0 |
| Lymph Node Palpation (week 56) Normal | 139 | 121 |
| Lymph Node Palpation (week 56) Abnormal NCS | 0 | 0 |
| Lymph Node Palpation (week 56) Abnormal CS | 0 | 1 |
| Musculoskeletal System (week -1) Normal | 131 | 128 |
| Musculoskeletal System (week -1) Abnormal NCS | 11 | 12 |
| Musculoskeletal System (week -1) Abnormal CS | 0 | 0 |
| Musculoskeletal System (week 56) Normal | 130 | 112 |
| Musculoskeletal System (week 56) Abnormal NCS | 9 | 9 |
| Musculoskeletal System (week 56) Abnormal CS | 0 | 1 |
| Respiratory System (week -1) Normal | 140 | 138 |
| Respiratory System (week -1) Abnormal NCS | 2 | 2 |
| Respiratory System (week -1) Abnormal CS | 0 | 0 |
| Respiratory System (week 56) Normal | 138 | 120 |
| Respiratory System (week 56) Abnormal NCS | 1 | 2 |
| Respiratory System (week 56) Abnormal CS | 0 | 0 |
| Skin (week -1) Normal | 116 | 114 |
| Skin (week -1) Abnormal NCS | 26 | 24 |
| Skin (week -1) Abnormal CS | 1 | 0 |
| Skin (week 56) Normal | 117 | 98 |
| Skin (week 56) Abnormal NCS | 21 | 24 |
| Skin (week 56) Abnormal CS | 1 | 0 |
| Thyroid Gland (week -1) Normal | 138 | 138 |
| Thyroid Gland (week -1) Abnormal NCS | 4 | 2 |
| Thyroid Gland (week -1) Abnormal CS | 0 | 0 |
| Thyroid Gland (week 56) Normal | 136 | 120 |
| Thyroid Gland (week 56) Abnormal NCS | 3 | 2 |
| Thyroid Gland (week 56) Abnormal CS | 0 | 0 |
Observed mean change in pulse rate measured at resting position is presented.
| beats/min | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Resting Pulse | 2 ± 10 | 1 ± 10 |
The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of subjects in each ECG category at baseline and week 56 are presented.
| participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Normal (week -1) | 100 | 91 |
| Abnormal NCS (week -1) | 41 | 49 |
| Abnormal CS (week -1) | 1 | 0 |
| Normal (week 56) | 102 | 81 |
| Abnormal NCS (week 56) | 36 | 42 |
| Abnormal CS (week 56) | 0 | 1 |
Observed mean change from baseline in haematological parameter blood haemoglobin.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements: Haematology (Haemoglobin Blood) | -0.2 ± 0.5 | -0.1 ± 0.6 |
Observed mean change from baseline in haematological parameter blood haematocrit. Haematocrit is presented as the percentage of red blood cells in total blood. Results based on SAS on-drug data is presented.
| percentage of red blood cells | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements: Haematology (Haematocrit Blood) | -1.5 ± 2.3 | -0.9 ± 2.6 |
Observed mean change from baseline in haematological parameter - erythrocytes.
| 10^12 cells/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements: Haematology (Erythrocytes) | -0.11 ± 0.25 | -0.08 ± 0.25 |
Observed mean change from baseline in haematological parameters - thrombocytss and leukocytes.
| 10^9 cells/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Thrombocytes | 4 ± 30 | 0 ± 36 |
| Leukocytes | -0.14 ± 1.53 | -0.11 ± 1.20 |
Observed mean change from baseline in biochemical parameter - albumin. Results based on SAS on-drug data is presented.
| g/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements: Biochemistry (Albumin) | -0.1 ± 0.2 | -0.1 ± 0.2 |
Observed mean change from baseline in biochemical parameters - alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase. Results based on SAS on-drug data is presented.
| U/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Alkaline Phosphatase | -2 ± 12 | -1 ± 13 |
| Alanine Aminotransferase | -5 ± 14 | -4 ± 16 |
| Amylase | 4 ± 10 | 1 ± 13 |
| Aspartate aminotransferase | -3 ± 10 | -2 ± 12 |
| Lipase | 7 ± 18 | 2 ± 22 |
Observed mean change from baseline in biochemical parameters - bilirubin and creatinine. Results based on SAS on-drug data is presented.
| umol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Bilirubin | 1.1 ± 3.2 | 1.0 ± 3.2 |
| Creatinine | -1.8 ± 7.9 | -1.4 ± 6.1 |
Observed mean change from baseline in biochemical parameters - total calcium, pottassium, sodium and urea. Results based on SAS on-drug data is presented.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Total Calcium | 0.01 ± 0.10 | 0.01 ± 0.09 |
| Potassium | -0.0 ± 0.5 | -0.0 ± 0.4 |
| Sodium | -0.0 ± 2 | -0 ± 2 |
| Urea | 0.0 ± 1.2 | 0.2 ± 1.2 |
Observed mean change from baseline in biochemical parameters - high sensitive c-reactive protein and uric acid. Results based on SAS on-drug data is presented.
| mg/dL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| High sensitive c-reactive protein | -2.51 ± 4.67 | -0.85 ± 8.96 |
| Uric acid | -0.6 ± 0.9 | -0.3 ± 0.9 |
Observed mean change from baseline in biochemical parameters - estimated glomerular filtration rate. Serum GFR is estimated using MDRD formula . Results based on SAS on-drug data is presented.
| mL/min/1.73m^2 | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum) | 2 ± 11 | 2 ± 9 |
Observed mean change from baseline in biochemical parameter - calcitonin. Results based on SAS on-drug data is presented.
| ng/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements: Biochemistry (Calcitonin) | 0.2 ± 0.8 | 0.1 ± 0.8 |
Observed mean change from baseline in biochemical parameters - thyroid stimulating hormone. Results based on SAS on-drug data is presented.
| mIU/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone) | -0.2313 ± 1.0366 | 0.2685 ± 3.6814 |
Collected over From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lira 3.0 mg | 0/142 (0%) | 6/142 (4.2%) | 124/142 (87.3%) |
| Placebo | 0/140 (0%) | 2/140 (1.4%) | 101/140 (72.1%) |
| Event | Lira 3.0 mg | Placebo |
|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/142 | 1/140 |
| HydrocephalusNervous system disorders | 0/142 | 1/140 |
| Cholecystitis acuteHepatobiliary disorders | 1/142 | 0/140 |
| ColitisGastrointestinal disorders | 1/142 | 0/140 |
| HeadacheNervous system disorders | 1/142 | 0/140 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/142 | 0/140 |
| Ovarian cystReproductive system and breast disorders | 1/142 | 0/140 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/142 | 0/140 |
| Event | Lira 3.0 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 68/142 | 25/140 |
| ConstipationGastrointestinal disorders | 43/142 | 26/140 |
| VomitingGastrointestinal disorders | 33/142 | 7/140 |
| Upper respiratory tract infectionInfections and infestations | 32/142 | 15/140 |
| DiarrhoeaGastrointestinal disorders | 31/142 | 23/140 |
| HeadacheNervous system disorders | 20/142 | 13/140 |
| SinusitisInfections and infestations | 9/142 | 18/140 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/142 | 16/140 |
| Back painMusculoskeletal and connective tissue disorders | 8/142 | 13/140 |
| InfluenzaInfections and infestations | 5/142 | 13/140 |
| Age, Continuous(Years) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 45.4 ± 11.6 | 49 ± 11.2 | 47.2 ± 11.5 |
| Sex: Female, Male(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Female | 119 | 116 | 235 |
| Male | 23 | 24 | 47 |
| Race (NIH/OMB)(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 27 | 22 | 49 |
| White | 112 | 115 | 227 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body weight(kg) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 108.5 ± 22.1 | 106.7 ± 22.0 | 107.6 ± 22.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Feb 2017 to primary completion in May 2018, 15 months.
Results were first posted in Jul 2019, 1 year 2 months after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 15 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide